Bristol-Myers Squibb said this week that it has appointed Vicki Sato to its board of directors.
Sato also sits on the board of Alnylam Pharmaceuticals.
Sato is currently a professor of molecular and cell biology at Harvard University, and previously served as president of Vertex Pharmaceuticals. Prior to this, she was vice president of research at Biogen, a biotechnology firm co-founded by Alnylam co-founder Phillip Sharp.
Products & Services
Ambion recently introduced its mirVana miRNA bioarrays V2, a version of the company's microRNA microarrays that includes probes targeting an exclusive set of 152 newly identified human miRNAs.
The new bioarrays also feature 22 control probes, the company said.